A Phase 2 in Adult Subjects With Hereditary Angioedema

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

March 30, 2028

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

BW-20805

SC administrations of BW-20805 600 mg on Day1 to Day673

DRUG

BW-20805

SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673

DRUG

BW-20805

SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589

Trial Locations (18)

12200

RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

17033

RECRUITING

Penn State Milton S. Hershey MC - Penn State, Hershey

20902

RECRUITING

Institute for Asthma and Allergy - Wheaton, Silver Spring

22031

RECRUITING

Inova Clinical Trials and Research Center, Falls Church

27705

RECRUITING

Duke University Medicine Center, Durham

35128

NOT_YET_RECRUITING

Azienda Ospedale - Universita di Padova, Padua

41013

RECRUITING

Hospital Universitario Virgen del Rocío, Seville

50134

RECRUITING

Azienda Ospedaliero-Universitaria Careggi, Florence

55101

RECRUITING

Universitätsmedizin der Johannes Gutenberg, Mainz

63141

RECRUITING

Washington University School of Medicine, St Louis

95125

RECRUITING

Azienda Ospedaliero Universitaria Policlinico G. Rodolico San Marco - Ospedale San Marco, Catania

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

130030

NOT_YET_RECRUITING

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

264000

RECRUITING

Yantai Yuhuangding Hospital, Yantai

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

650032

RECRUITING

First Affiliated Hospital of Kunming Medical University, Kunming

730000

RECRUITING

The First Hospital of Lanzhou University, Lanzhou

31-066

NOT_YET_RECRUITING

SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow

All Listed Sponsors
lead

Shanghai Argo Biopharmaceutical Co., Ltd.

INDUSTRY